First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study
15th February 2016 - 1:55 pm
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease.
ImmuPharma is pleased to confirm that the first US sites opened in December 2015 have now commenced dosing patients. Recruitment in this pivotal Phase III study for Lupuzor™ will occur in up to 45 investigator sites. 10 sites in United States and 35 in Europe.
Further updates on the progression of the Lupuzor™ Phase III trial will be announced, as appropriate, as the trial progresses. Progress on the trial can also be seen at: www.ClincialTrials.gov/lupuzor.
Commenting on the event, Tim McCarthy, Chairman, said: “This is the next key milestone for ImmuPharma’s Lupuzor™ trial and we are therefore delighted that following the initial US sites being opened, we can now confirm that the first Lupus patients have commenced dosing. With recruitment going to plan, we look forward to providing further positive updates on this Lupuzor™ Phase III study as it progresses throughout this year and 2017.”